These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16000582

  • 1. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.
    Clin Cancer Res; 2005 Jul 01; 11(13):4843-50. PubMed ID: 16000582
    [Abstract] [Full Text] [Related]

  • 2. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May 01; 63(6):1049-63. PubMed ID: 18791718
    [Abstract] [Full Text] [Related]

  • 3. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May 01; 63(6):1035-48. PubMed ID: 18791717
    [Abstract] [Full Text] [Related]

  • 4. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ.
    Clin Cancer Res; 2004 Dec 15; 10(24):8325-31. PubMed ID: 15623609
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.
    Clin Cancer Res; 2002 May 15; 8(5):1038-44. PubMed ID: 12006516
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen.
    Mielke S, Sparreboom A, Behringer D, Mross K.
    Anticancer Res; 2005 May 15; 25(6C):4423-7. PubMed ID: 16334120
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A.
    J Clin Oncol; 2002 Jan 15; 20(2):574-81. PubMed ID: 11786588
    [Abstract] [Full Text] [Related]

  • 8. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N.
    Clin Cancer Res; 2005 Jun 01; 11(11):4136-43. PubMed ID: 15930349
    [Abstract] [Full Text] [Related]

  • 9. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 10. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH.
    Clin Cancer Res; 1999 Nov 16; 5(11):3379-84. PubMed ID: 10589748
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK.
    Cancer Chemother Pharmacol; 2002 May 16; 49(5):367-74. PubMed ID: 11976830
    [Abstract] [Full Text] [Related]

  • 12. Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
    Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C.
    Clin Cancer Res; 2001 May 16; 7(5):1192-7. PubMed ID: 11350883
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR.
    Clin Cancer Res; 2008 Sep 15; 14(18):5856-63. PubMed ID: 18794097
    [Abstract] [Full Text] [Related]

  • 14. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

  • 15. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
    Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N.
    Clin Cancer Res; 1995 Jun 15; 1(6):599-606. PubMed ID: 9816021
    [Abstract] [Full Text] [Related]

  • 16. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
    Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ, Cancer and Leukemia Group B (CALGB 9762).
    J Clin Oncol; 2006 Apr 20; 24(12):1846-51. PubMed ID: 16567769
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ.
    Clin Cancer Res; 2004 Jun 01; 10(11):3708-16. PubMed ID: 15173077
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
    Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD.
    J Clin Oncol; 2005 Nov 01; 23(31):7785-93. PubMed ID: 16258082
    [Abstract] [Full Text] [Related]

  • 19. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K.
    Clin Pharmacol Ther; 1998 Nov 01; 64(5):511-21. PubMed ID: 9834043
    [Abstract] [Full Text] [Related]

  • 20. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH.
    Br J Cancer; 2001 Jan 05; 84(1):42-7. PubMed ID: 11139311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.